Consistently, combined inhibition of SMYD3 and PARP, which is one of the most studied DDR targets, emerged as a promising synthetic lethality strategy in HR-proficient gastrointestinal and breast cancers expressing high levels of SMYD3 [20]. The gene discussed is SMYD3; the disease is breast carcinoma.